Thus, by controlling METTL3/HIF-1/MYC signaling in oral cancer, our investigations reveal a previously unidentified connection between arecoline and cisplatin resistance that may help develop strategies to overcome the challenge of cisplatin resistance in OSCC patients. The gene discussed is METTL3; the disease is lip and oral cavity carcinoma.